Urinary Biomarkers for Detection of Clinical Endometriosis or Adenomyosis.

Endometriosis or adenomyosis can be clinically diagnosed by ultrasound, symptoms, physical examination, and serum CA125. The urinary markers need to be investigated. The aim of our study was to investigate the urinary markers of clinical endometriosis/adenomyosis, and the correlation of serum CA125 was also studied. From the literature, alpha-1 antitrypsin (A1AT), enolase-1, vitamin D binding protein (VDBP), and CA125 in urine and serum were used in our study and measured by enzyme-linked immunosorbent assays (ELISA). Further clinical correlation and detection performance were evaluated. We enrolled 19 normal controls and 33 patients clinically diagnosed with endometriosis/adenomyosis. There were significant differences between studied patients and normal controls, as follows: serum CA125 (130.91 vs. 19.75 U/mL, = 0.004); urinary CA125-creatinine ratio (5.591 vs. 0.254 ng/mg, = 0.028); and urinary VDBP-creatinine ratio (28.028 vs. 7.301 ng/mg, = 0.018). For diagnostic performances, serum CA125 provided the best results, with an area under curve (AUC) of 0.888 ( = 0.001) and accuracy of 86.5%. Other excellent results were also found using urinary VDBP (AUC 0.841, = 0.001) and A1AT (AUC 0.722, = 0.011) creatinine ratio. Using three combined biomarkers, serum CA125, urinary VDBP, and A1AT creatinine ratio, provided good detection power (AUC 0.913, = 0.001, sensitivity 90.9%, specificity 76.5%). Double urine markers used in combination with VDBP and A1AT creatinine ratio also provided good diagnostic performance (AUC 0.809, = 0.001, sensitivity 81.8%, specificity 76.5%, accuracy 80%). Further development of non-invasive point-of-care tests using these biomarkers could be a fruitful future endeavor.